Prevalence of Telogen Effluvium in Egyptian Women with Post Covid 19 Viral Infections Compared to Post-Partum Telogen Effluvium

Hamed Mohamed Abdo

Departement of Dermatology and Venereology, Faculty of Medicine, Al Azhar University, Egypt.

Ahmed S. Kadah *

Departement of Dermatology and Venereology, Al-Hussin University Hospital, Al-Azhar University, Egypt.

Ahmed H. Nouh

Departement of Dermatology and Venereology, Faculty of Medicine, Al Azhar University, Egypt.

Maged Elsheikh

Department of Dermatology and Venereology, Military Medical Academy, Egypt.

Hamza Mohammed Saqaan

Dnipropetrovsk State Medical Academy, Ukraine.

Marwa Said

Departement of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.

*Author to whom correspondence should be addressed.


Introduction: Telogen effluvium is considered if the hair shedding occurs within three months of the triggering factor. It is self-limited lasting about 6 months.  Post-partum TE is reported as hair loss postpartum and it is usually overestimated due to associated stress and psychological problems. Post-acute COVID-19 is a syndrome characterized by the persistence of clinical symptoms beyond four weeks after the onset of acute symptoms.

Aim: To highlight the prevalence of telogen effluvium in Egyptian women with post-Covid 19 viral infections compared to post-partum telogen effluvium.

Methods: This comparative studyThis study is comparative study was conducted on 50 female patients diagnosed with COVID-19 viral infections in the previous few weeks to months and another 50 post-partum females. Written consent will be obtained from all participants in the study.

Results: 70.6% of the post-covid cases had normal trichoscopic findings compared to 33.4% of postpartum cases, and 29.4% of post-covid cases had abnormal trichoscopic findings compared to 66.6% of postpartum cases. The empty follicles and reduction in hair follicle density is the main trichoscopic finding in post covid cases (84%, and 70 %respectively) compared to upright regrowing hair in postpartum cases 77%. 

Conclusion: TE can be considered one of the symptoms of post-covid syndrome as well as post-partum hair loss in Egyptian females.

Keywords: Post-covid syndrome, post-covid Telogen effluvium, post-partum Telogen effluvium

How to Cite

Abdo , Hamed Mohamed, Ahmed S. Kadah, Ahmed H. Nouh, Maged Elsheikh, Hamza Mohammed Saqaan, and Marwa Said. 2023. “Prevalence of Telogen Effluvium in Egyptian Women With Post Covid 19 Viral Infections Compared to Post-Partum Telogen Effluvium”. Asian Journal of Research in Dermatological Science 6 (1):95-101.


Download data is not yet available.


Harrison S, Sinclair R. Telogen effluvium. Clinical and Experimental Dermatology. 2002;27(5): 389-395.

Mirallas O, Grimalt R. The postpartum telogen effluvium fallacy. Skin Appendage Disorders. 2015;1(4):198-201.

Alonso L, Fuchs E. The hair cycle. Journal of Cell Science. 2006;119(3):391-393.

Trüeb RM, Dutra Rezende H, Gavazzoni Dias MFR. What can the hair tell us about COVID‐19? Experimental Dermatology. 2021;30(2):288-290.

Tammaro A. et al. Hair and nail manifestations of COVID‐19. Journal of Cosmetic Dermatology, 2022;21(4):1339-1346.

Seyfi S et al. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. Journal of Medicine and Life. 2022; 15(5):631.

Olds H et al. Telogen effluvium associated with COVID‐19 infection. Dermatologic Therapy. 2021;34(2):e14761.

Aktaş H, Hamidi AA. Urticaria in a patient with COVID‐19: Therapeutic and diagnostic difficulties. Dermatologic Therapy. 2020;3 3(4):e13610.

Di Landro A et al., Pathobiology questions raised by telogen effluvium and trichodynia in COVID‐19 patients. Experimental Dermatology. 2021;30(7):999.

Ito T et al. Interferon‐γ is a potent inducer of catagen‐like changes in cultured human anagen hair follicles. British Journal of Dermatology. 2005;152(4):623-631.

Jose RJ, Manuel A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. The Lancet Respiratory Medicine. 2020;8(6):e46-e47.

Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation, and repurposing antirheumatic drugs. Turkish Journal of Medical Sciences. 2020;50(9):620-632.

Gupta G et al. Emerging dermatological symptoms in coronavirus pandemic. Journal of Cosmetic Dermatology. 2020; 19(9):2447.

Goldust M et al. Use of face masks in dermatology department during the COVID‐19 outbreak. Dermatologic Therapy. 2020;33(5).

Shome D et al. Efficacy of QR678 Neo® hair growth factor formulation for the treatment of hair loss in Covid‐19‐induced persistent Telogen Effluvium—A prospective, clinical, single‐blind study. Journal of Cosmetic Dermatology. 2022;21 (1):16-23.

Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium. Irish Journal of Medical Science (1971). 2022;191(4):1677-1681.

Hussain N et al. A systematic review of acute telogen effluvium, a harrowing post‐COVID‐19 manifestation. Journal of Medical Virology. 2022;94(4):1391-1401.

Kutlu Ö. Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID‐19 pandemic. Dermatologic Therapy. 2020;33(6):e13949.

Lynfield YL. Effect of pregnancy on the human hair cycle. Journal of Investigative Dermatology. 1960;35(6):323-327.

Gizlenti S, Ekmekci T. The changes in the hair cycle during gestation and the postpartum period. Journal of the European Academy of Dermatology and Venereology. 2014;28(7)::878-881.

Malkud S. Telogen effluvium: A review. Journal of Clinical and Diagnostic Research: JCDR, 2015;9(9):WE01.